ATE405828T1 - Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik - Google Patents

Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik

Info

Publication number
ATE405828T1
ATE405828T1 AT06113906T AT06113906T ATE405828T1 AT E405828 T1 ATE405828 T1 AT E405828T1 AT 06113906 T AT06113906 T AT 06113906T AT 06113906 T AT06113906 T AT 06113906T AT E405828 T1 ATE405828 T1 AT E405828T1
Authority
AT
Austria
Prior art keywords
clinics
biomarkers
cdk inhibitors
response monitoring
mammal
Prior art date
Application number
AT06113906T
Other languages
English (en)
Inventor
Wanda Eve Depinto
Xuefeng Yin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE405828T1 publication Critical patent/ATE405828T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT06113906T 2005-05-25 2006-05-15 Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik ATE405828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68450205P 2005-05-25 2005-05-25

Publications (1)

Publication Number Publication Date
ATE405828T1 true ATE405828T1 (de) 2008-09-15

Family

ID=36954240

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06113906T ATE405828T1 (de) 2005-05-25 2006-05-15 Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik

Country Status (9)

Country Link
US (1) US20060269482A1 (de)
EP (1) EP1726953B1 (de)
JP (1) JP2006325593A (de)
CN (1) CN101078716A (de)
AT (1) ATE405828T1 (de)
CA (1) CA2545426A1 (de)
DE (1) DE602006002311D1 (de)
ES (1) ES2313556T3 (de)
SG (1) SG127843A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114828B2 (en) 2007-04-16 2012-02-14 Honeywell International Inc. Azeotrope-like compositions of tetrafluoropropene and alcohols
WO2013071415A1 (en) * 2011-11-15 2013-05-23 University Health Network Targeting the rb pathway for the prevention of cancer
CN116240261B (zh) * 2023-02-22 2024-05-14 迈杰转化医学研究(苏州)有限公司 一种检测pbmc中shp2抑制剂活性的试剂盒及其方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828752B2 (ja) * 1999-08-04 2011-11-30 株式会社医学生物学研究所 サイクリン/cdk複合体のリン酸化酵素活性測定方法
US20030166016A1 (en) * 2000-04-28 2003-09-04 Foster Barbara A. Assay methods for cyclin dependent kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives

Also Published As

Publication number Publication date
JP2006325593A (ja) 2006-12-07
CN101078716A (zh) 2007-11-28
SG127843A1 (en) 2006-12-29
EP1726953A1 (de) 2006-11-29
CA2545426A1 (en) 2006-11-25
ES2313556T3 (es) 2009-03-01
DE602006002311D1 (de) 2008-10-02
US20060269482A1 (en) 2006-11-30
EP1726953B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
ATE488765T1 (de) Verfahren zum frühen nachweis einer nierenkrankheit und -verletzung
DK2360475T3 (da) Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
ATE531820T1 (de) Gesundheitszustandstest
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
DE602005025106D1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
ATE537450T1 (de) Igfbp2-biomarker
BRPI0715126B8 (pt) métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
EP1802766A4 (de) Verfahren für einen globalen gerinnungs- und fibrinolysetest
MX2022005159A (es) Uso de biomarcadores para predecir la sensibilidad clinica a 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin- 5-il)metil)-2,2-difluoroacetamida.
JP2014532168A5 (de)
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
JP2008514209A5 (de)
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
NO20055025D0 (no) Multiplex screening for lysosomale lagringsforstyrrelser (LSD)
EP2044212A4 (de) Verfahren zur identifizierung von patienten mit erhöhtem risiko für ein unerwünschtes herz-kreislauf-ereignis
ATE405828T1 (de) Biomarker zur reaktionsüberwachung von cdk- hemmern in der klinik
WO2010045224A3 (en) Methods for the selection of therapeutic treatments for cancer
ATE464395T1 (de) Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
WO2008012692A3 (en) Assay for efficacy of histone deacetylase inhibitors
EP2183385A4 (de) Verfahren zur bestimmung einer proteinphosphatase-aktivität sowie seine anwendung bei der prognose von therapieergebnissen
ATE543914T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
WO2007127002A3 (en) Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
ATE443871T1 (de) Test zum nachweis von pathologischen prionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties